Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers

Summary

The purpose of this study is to determine the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prophylaxis of visceral leishmaniasis. The vaccine, identified as LEISH-F3 + GLA-SE, consists of the recombinant two-antigen Leishmania recombinant protein LEISH-F3 together with the adjuvant GLA-SE.

Timeline

Start

2012-01

Primary completion

2012-08

Completion

2013-05

Drugs

Indications